Peer-reviewed veterinary case report
Retrospective analysis for treatment of naïve canine multicentric lymphoma with a 15‐week, maintenance‐freeCHOPprotocol
- Journal:
- Veterinary and Comparative Oncology
- Year:
- 2015
- Authors:
- Curran, K. & Thamm, D. H.
- Affiliation:
- Flint Animal Cancer Center Colorado State University Fort Collins CO USA · United States
- Species:
- dog
Plain-English summary
In this study, researchers looked at a group of 134 dogs with multicentric lymphoma, a type of cancer that affects the lymph nodes. These dogs were treated with a 15-week chemotherapy plan that included a combination of four drugs, but without the need for ongoing maintenance treatments afterward. The results were very promising, with 98% of the dogs responding to the treatment and 104 of them achieving complete remission, meaning their cancer was no longer detectable. On average, the dogs lived for about 311 days after starting treatment, which is a good outcome for this condition. Overall, this shorter treatment plan could be a good option for pet owners who are concerned about the time and resources needed for longer chemotherapy protocols.
Abstract
AbstractStandard of care treatment of dogs with multicentric lymphoma includes combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP); however, owners may be hesitant to commit the resources necessary to complete a lengthy, multi‐drug protocol. One hundred thirty‐four client‐owned dogs with multicentric lymphoma were treated with a 15‐weekCHOPchemotherapy protocol. The overall response rate was 98% with 104 dogs experiencing a complete response (CR). The median progression‐free survival (PFS) time for all dogs was 176 days, and the median disease‐specific overall survival time was 311 days. Prognostic factors identified on multivariate analysis as significant forPFSincluded substage, immunophenotype, hospitalization for adverse events, need for dose reduction, presence of neutrophilia at diagnosis, presence of anemia and experiencing aCRas best response to therapy. In conclusion, this protocol may be a viable alternative toCHOPprotocols using a larger number of treatments.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://doi.org/10.1111/vco.12163